Document text
Principal Investigator: KELVIN P. LEE
Organization: INDIANA UNIVERSITY INDIANAPOLIS
Fiscal Year: 2024
Award: $481,430
Funding agency: National Cancer Institute
ABSTRACT, Leadership, Planning, and Evaluation
The Indiana University Simon Comprehensive Cancer Center (IUSCCC) has established an effective process
for Leadership, Planning, and Evaluation that receives input from its senior leaders, Research Program leaders,
and members as well as internal and external advisory committees. The current grant period has seen
recruitment of a new Director (Dr. Kelvin Lee) and expansion of the senior leadership team to oversee new
IUSCCC-wide initiatives through creation of Associate Director positions in Data Science (Dr. Kun Huang),
Diversity, Equity, and Inclusion (Dr. Antwione Haywood), and System Integration (Ms. Katie McGill, IU Health).
These changes have enhanced formal strategic integration and coordination among IUSCCC, the IU School of
Medicine (IUSM), and the IU Health system. Based on internal and external input, the IUSCCC leadership has
developed and implemented its Strategic Plan and has continuously assessed the plan's impact on the four
Research Programs and multiple Shared Resources in advancing the IUSCCC mission to serve the population
of Indiana and beyond. The Strategic Plan has evolved from 2018 through its most recent update in 2023 to a
framework that contains three major components: Foundational Organizational Capabilities; Integrating Efforts
(education, data science, community outreach and engagement); and Cross-Cutting Scientific Themes
(mechanism-based medicine, bench↔bedside↔main street translational research, population health, social
responsibility and policy). Following this Strategic Plan, the senior leadership has implemented a number of
actions over the current grant period. These include appointment of new leadership in the four Research
Programs: Cancer Prevention and Control (Dr. Katzenellenbogen), Experimental and Developmental
Therapeutics (Drs. Opyrchal and Pollok), Tumor Microenvironment and Metastasis (Dr. Fishel), and
Hematopoiesis and Hematologic Malignancies (Dr. Salman). Additionally, new transdisciplinary research
initiatives (e.g., the Brown Center for Immunotherapy), translational development platforms (e.g., the Cancer
Drug Discovery and Development Accelerator), and educational programs (e.g., the Translational Cancer
Biology PhD program) have been launched. There has also been significant expansion of the Office of
Community Outreach and Engagement and development of the Plan to Enhance Diversity (PED). These and
other initiatives drive IUSCCC's mission to impact research, patient care, and education both locally and globally.
To accomplish these, the Leadership, Planning, and Evaluation aims are to: 1) further increase the depth of
Team Science, both intra- and extramurally, geared towards reducing the burden of cancer, 2) amplify cancer
outreach and community engagement activities within our catchment area and beyond, 3) create a strong
planning process that aligns the tripartite mission of IUSCCC, IUSM, and the clinical enterprise through strategic
planning, 4) expand our educational footprint from teens to tenure, and 5) implement the PED.
Terms: <Advisory Committees><Anti-Cancer Agents><Antineoplastic Agents><Antineoplastic Drugs><Antineoplastics><Appointment><Bio-Informatics><Bioinformatics><Biometrics><Biometry><Biostatistics><CCSG><Cancer Biology><Cancer Burden><Cancer Center Support Grant><Cancer Control><Cancer Control Science><Cancer Drug><Cancers><Catchment Area><Clinical><Community Outreach><Comprehensive Cancer Center><Data Science><Development><Development Plans><Developmental Therapeutics><Developmental Therapeutics Program><Developmental Therapy><Doctor of Philosophy><EXTMR><Education><Educational aspects><Evaluation><Experimental Therapies><Extramural><Extramural Activities><Feedback><Grant><Health><Health system><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoiesis><Hematopoietic Cancer><Hematopoietic Cellular Control Mechanisms><Immune mediated therapy><Immunologically Directed Therapy><Immunotherapy><Indiana><Investigational Therapies><Investigational Treatments><Investigators><Leadership><Malignant Hematologic Neoplasm><Malignant Neoplasms><Malignant Tumor><Medicine><Metastasis><Metastasize><Metastatic Lesion><Metastatic Mass><Metastatic Neoplasm><Metastatic Tumor><Mission><National Cancer Burden><Neoplasm Metastasis><Neoplastic Disease Chemotherapeutic Agents><Patient Care><Patient Care Delivery><Ph.D.><PhD><Population><Position><Positioning Attribute><Process><Research><Research Personnel><Researchers><Resource Sharing><Science><Secondary Neoplasm><Secondary Tumor><Services><Social Policies><Social Responsibility><Strategic Planning><Systems Integration><Task Forces><Teen><Teenagers><Textiles><Translational Research><Translational Science><Tumor-Specific Treatment Agents><Universities><Update><advisory team><anti-cancer drug><bench bed side><bench bedside><bench to bed side><bench to bedside><bench to clinic><bench to clinical practice><blood cell formation><cancer metastasis><cancer microenvironment><cancer prevention><care for patients><care of patients><caring for patients><community engagement><developmental><diversity, equity, and inclusiveness><drug development><drug discovery><engagement with communities><equity, diversity, and inclusion><experimental therapeutic agents><experimental therapeutics><fabric><immune therapeutic approach><immune therapeutic interventions><immune therapeutic regimens><immune therapeutic strategy><immune therapy><immune-based therapies><immune-based treatments><immuno therapy><integrated system><malignancy><medical college><medical schools><member><neoplasm/cancer><next generation><outreach><population health><programs><recruit><school of medicine><system integration><teen years><teenage><translation research><translational investigation><tumor cell metastasis><tumor microenvironment>